Member Spotlight: United Therapeutics Corporation
By Martine Rothblatt, PhD, Chairman and CEO of United Therapeutics Corporation.
Founded in 1996, United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. We have four approved products on the market today and we are not stopping there! From the United States to Europe to the Asia Pacific, we are proud of our multicultural business environment where employees can collaborate with people all over the world. As a group, we are relentless in our pursuit of “medicines for life”® and continue our research into treatments for pulmonary arterial hypertension, cancer, and some of the world’s most complicated viral illnesses.
We are proud to partner with Research!America to promote better medical advancements, biomedical research, and overall greater global health initiatives. We have seen first-hand how tireless research and dedication to a cause can change the lives of thousands of patients and their loved ones. We began our story by conducting extensive research on a treatment for a deadly disease so rare, Pulmonary Arterial Hypertension (PAH), that other medical companies had abandoned any pursuits for treatments or a cure. Continue reading →
Member spotlight: Texas Biomedical Research Institute
By Robert Gracy, PhD, CEO of Texas Biomedical Research Institute
Now in its eighth decade of existence, the Texas Biomedical Research Institute in San Antonio, Texas, has a mission “to improve the health of our global community through innovative biomedical research.” Texas Biomed has a breadth and depth of scientific inquiry coupled with an unparalleled collection of research resources, which in combination provides its researchers unique capabilities. Texas Biomed also views partnering with Research!America – a strong advocate for growing our country’s investment in biomedical funding – as retaining an effective ally in maintaining and eventually strengthening the backbone of our country’s preeminent position in the biomedical research field.
In the Department of Genetics, researchers are examining the genes related to complex diseases such as cardiovascular illness, diabetes, obesity, metabolic syndrome, macular degeneration, behavioral and psychiatric disorders, arthritis and osteoporosis – hoping to ultimately provide the foundation of knowledge that can lead to better treatment of these devastating illnesses and to personalize care according to the genetic profile of each patient. Continue reading →
What would it take to achieve a cancer-free world?
Excerpt of an article by Research!America VP of Communications Suzanne Ffolkes and Communications Specialist Anna Briseno, published in Elsevier Connect.
A panel hosted by Research!America and the Pancreatic Cancer Action Network discusses challenges and opportunities for advancing cancer research
Julie Fleshman’s journey to improve outcomes for pancreatic cancer patients was inspired by her father, who died four months after receiving the diagnosis. That was in 1999. Since then, she’s been advocating for research to support early diagnosis and better treatments.
“That passion drives me every day – anger mixed with hope and optimism of the future,” she said.
Fleshman, President and CEO of the Pancreatic Cancer Action Network (PanCAN), made her remarks on a panel at the New York Academy of Sciences February 27.
Thought leaders from industry, academia, health economics and patient advocacy discussed challenges and opportunities for advancing cancer research and the prospects for a future where cancers are rendered manageable or even eradicated. They examined various aspects of cancer research and patient advocacy from a regulatory, policy and clinical standpoint. They spoke of the challenges posed by regulatory barriers and the role of advocates in fostering medical innovation. And they said there was critical need for collaboration among all stakeholders – including representatives from pharma, medicine, academia, the government and patient organizations – to accelerate medical progress.
The event – called A World Free from Cancer: A Road Paved with Medical Innovation – was hosted by Research!America and PANCAN.
Fleshman began the discussion by talking about the rise of the patient advocate who plays “an extremely important role in helping to change outcomes and … raise the awareness in the public, which drives public and private dollars and moves Congress to action.”
Laurie MacCaskill, a seven-year pancreatic cancer survivor, agreed. “Luck shouldn’t play a role in why I’m alive,” she said.
Dr. Amy Abernethy suggested that society should work toward better matching treatments and patients so resources aren’t wasted. She highlighted the need for extensive risk and benefit analysis to maximize opportunities for improved healthcare delivery.
MacCaskill agreed, noting it’s important for cancer patients to know what treatment options are available that best suit their needs. She said stakeholders need to work together to develop solutions that increase access.
Read the full article here.
US Biomedical Research: We Must Reverse a Decade of Neglect
Excerpt of an op-ed by the Albert and Mary Lasker Foundation President Claire Pomeroy, MD, published in the Huffington Post.
As an HIV physician, I began my career early in the AIDS epidemic before effective antiviral medications existed. I held my patients’ hands as they cried when receiving their diagnosis and I went to their funerals. I saw hope in their eyes when new antivirals became available. And when protease inhibitors were licensed and “triple therapy” became the norm, I could help patients plan how they would live, rather than how they would die. Scientific breakthroughs happened only because of our nation’s commitment to biomedical research, but this power of research to make lives better is at great risk.
The decline of U.S. prominence in global biomedical research is upon us: The National Institutes of Health budget has been flat for 10 years and lost 25 percent of its purchasing power, sequestration cut $1.7 billion from the 2013 NIH budget and the 2014 budget is $714 million less than the level approved for 2013, the federal government shutdown prevented enrollment of patients into clinical studies and delayed clinical research protocols, and next generation researchers are taking ideas and talents to other countries. The U.S. sits on the sidelines as nations such as China and India increase research investment by nearly 20 percent while the U.S. drops by 5 percent.
The government’s failure to ensure significant ongoing support for biomedical research undermines the future of science and health in our nation and threatens a strategic driver of the economy. The call to action is clear: The research community must increase advocacy, develop novel research partnerships, and create new opportunities for young researchers.
Read the full op-ed here.
Member spotlight: the Association for Psychological Science
By Alan G. Kraut, Executive Director of the Association for Psychological Science
In the minds of many people, there is a separation between biomedical research and behavioral research. But that separation is artificial. Behavior is at the core of many health problems. Six out of 10 of the leading causes of premature death, including heart disease, diabetes, and stroke, are linked in part to genetic influences but also to controllable behaviors like physical inactivity, poor diet and smoking.
Our 25,000 members are scientists and educators at the nation’s universities and colleges, conducting federally funded basic and applied, theoretical, and clinical research. They look at such things as the connections between emotion, stress, and biology and the impact of stress on health; they look at ways to manage debilitating chronic conditions such as diabetes and arthritis as well as depression and other mental disorders; they look at how genes and the environment influence behavioral traits such as aggression and anxiety; and they address the behavioral aspects of smoking and drug and alcohol abuse.
Just as there exists a layered understanding, from basic to applied, of how molecules affect brain cancer, there is a similar spectrum for behavioral research. Continue reading →
Don lab coats
Letter to the editor by Research!America President and CEO Mary Woolley published in the Philadelphia Inquirer.
By visiting a University of Pennsylvania research facility last week, Sen. Bob Casey (D., Pa.) underscored his commitment to making research and innovation an immutable national priority (“Scientists reeling from budget cuts,” Oct. 24). Adequately supported, research will allow us to overcome major health threats and drive the economy.
Americans have taken notice that research support is waning and, in addition, say they are concerned that officials in Washington are not paying enough attention to deadly diseases, polling done for our nonprofit advocacy alliance, Research!America, shows. If elected officials aren’t paying attention, who will lead the charge to assure robust funding for research now and in the future? Too many lives hang in the balance if we take medical progress for granted. Cures and treatments for deadly and disabling diseases can’t wait out nine more years of sequestration.
Share Your Story: How You Can Fight for Tomorrow’s Medical Breakthroughs
By Endocrine Society President Teresa K. Woodruff, PhD
The sad stories flow in each day. A post-doctoral fellow gives up scientific research after 10 years of training. A cancer researcher faces a fruitless job search and expiring visa. The endocrinologist agonizes over letting a long-time lab employee go.
Hundreds of these tales are unfolding across the country as the National Institutes of Health struggles to stretch its dwindling budget. Because of sequestration, an NIH budget that barely kept pace with inflation through the 1990s and early 2000s was slashed by another $1.6 billion this fiscal year. If Congress cannot agree on a more balanced approach to budget cuts, another $6.7 billion in needed biomedical research funding will disappear in Fiscal Year 2014. The NIH funding cuts are nothing short of a disaster for biomedical science in the United States, as the Society journal Endocrinology’s Editor-in-Chief Andrea C. Gore observed in a recent editorial.
It is disheartening to think of the treatments that won’t be developed, the discoveries that won’t be made and the patients who will suffer as a result of Congress’ short-sighted funding decisions. As president of The Endocrine Society, I saw firsthand at the Society’s annual meeting ENDO 2013 just how many breakthroughs our researchers are making to ultimately improve the lives of people who have conditions like diabetes, thyroid disorders and cancer. Without biomedical research funding, promising scientific avenues won’t be explored and fewer new treatments will be available to patients in the years to come.
In my own lab at Northwestern University, we instituted a hiring freeze after our grant award was halved. Now we won’t be able to investigate some key questions, such as how endocrine-disrupting chemicals in our environment impact reproductive health.
But there are actions we as researchers and scientists can take to avert the worst effects of this crisis. Congress and the public need to know how much pain the sequester is causing by delaying breakthroughs in treating infertility, heart disease and metabolic disorders. Congress should reverse course. Take a moment to share your story with your Members of Congress, your hometown newspaper, or a health organization like The Endocrine Society, Research!America or United for Medical Research. By raising our voices as one, we can rewrite the story’s ending and protect our nation’s biomedical research legacy.
2014 Lurie Prize in Biomedical Sciences
The Foundation for the National Institutes of Health (FNIH) is accepting nominations for the 2014 Lurie Prize in the Biomedical Sciences, an annual award recognizing outstanding achievement by a young scientist in biomedical research.
The Prize? $100,000, made possible by a generous gift from Ann Lurie, FNIH Board Member, distinguished philanthropist and president of the Ann and Robert H. Lurie Foundation.
A few things to remember if you want to apply: the nominator must be a member of an accredited educational and/or scientific institution; the candidate must be 52 or younger on January 1, 2014; all nomination materials must be in English; and no self-nominations are allowed.
The awardee will be selected by a jury of six distinguished biomedical researchers, chaired by Solomon H. Snyder, MD, Distinguished Service Professor of Neuroscience, Pharmacology & Psychiatry of the Solomon H. Snyder Department of Neuroscience at Johns Hopkins University School of Medicine.
Last year’s winner was Ruslan M. Medzhitov, PhD, the David W. Wallace Professor of Immunobiology at Yale University School of Medicine and a Howard Hughes Medical Institute Investigator for discoveries related to the immune system. The innate immune system that Medzhitov studies rapidly mobilizes a response to infection and, together with the adaptive immune system, is crucial to protecting human health.
Deadline to submit nominations is October 1, 2013, at 1 p.m. Eastern.
If you have any questions, email lurieprizeinfo@fnih.org.
Research Matters Communications Workshop, October 9
Promoting Basic Research in a New Age of Communications: Challenges and Opportunities
REGISTER HERE.
Scientists, journalists and policy makers. What do they all have in common? They all are trained (in very different ways) to ask the hard questions while serving the public interest. Often the lines of communications between these three professions are weak or, sometimes, non-existent. A greater understanding between them is needed to demonstrate the value and the return on investment of basic biomedical research.
On October 9, 2013, join Research!America, Cold Spring Harbor Laboratory, Elsevier, The George Washington University and the Society for Neuroscience for a workshop designed to enhance the ability of early-career scientists to effectively communicate their research to various audiences and become stronger advocates.
Plenary session speaker:
- Christie Nicholson, lecturer at the Alan Alda Center for Communicating Science at Stony Brook University.
Moderators:
- Frank Sesno, director of the School of Media and Public Affairs at The George Washington University
- Debra Lappin, JD, principal, FaegreBD Consulting and Research!America Board member
Panelists:
- Cara Altimus, PhD, executive board member, Johns Hopkins Postdoc Association
- Nick Bath, JD, senior health policy advisor, Senate HELP Committee
- Patrick Carroll, legislative director, Rep. Kevin Yoder (R-KS)
- Susan Heavey, health correspondent, Reuters
- Patricia Knight, founder, Knight Capitol Consultants, LLC; former chief of staff, Sen. Orrin Hatch (R-UT)
- Jonathan Moreno, PhD, editor-in-chief, Science Progress blog; senior fellow, Center for American Progress
- Nancy Shute, health and medicine reporter, NPR
- Dan Smith, JD, principal, The Sheridan Group; founder and former president of the American Cancer Society Cancer Action Network
The program includes a plenary session by the Alan Alda Center for Communicating Science at Stony Brook University; two panel discussions with leaders in science, health communications, journalism, public health and public policy; and a session with top Elsevier editors on techniques for getting published in scientific journals.
Register for half off the admission price now through Friday, September 27: $37.50 for participants affiliated with Research!America members and $75 for participants not affiliated with Research!America members. (If you’ve already registered, we will offer a partial refund.)
Registration deadline has been extended to Friday, September 27.
For more information, visit www.researchamerica.org/communicationsworkshop
Research!America Blog 